Nkarta, Inc. filed a current report on Form 8-K on November 6, 2026, disclosing that the company will host a webcast on November 9, 2026, to review initial clinical data from its Ntrust clinical program evaluating NKX019 in myositis and systemic sclerosis.

Key Highlights

  • Webcast scheduled: Nkarta will host a webcast on Monday, November 9, 2026, at 8:00 a.m. Eastern Time.
  • Clinical program: The webcast will review initial clinical data from the Ntrust clinical program evaluating NKX019.
  • Indications covered: NKX019 is being evaluated in myositis and systemic sclerosis, according to the filing.
  • Conference presentation: The data is being presented at the American College of Rheumatology (ACR) Convergence 2026.
  • Press release furnished: A press release issued November 6, 2026, was attached as Exhibit 99.1 and furnished under Regulation FD.
  • Signing officer: The report was signed by Nadir Mahmood, President of Nkarta, Inc.

Nkarta Discloses NKX019 Data Webcast Tied to ACR Convergence 2026

Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage company incorporated in Delaware and headquartered in South San Francisco, California, filed an 8-K with the SEC on November 6, 2026, under Item 7.01 Regulation FD Disclosure. According to the filing, the company issued a press release on that same date announcing a planned webcast to present initial clinical data from its Ntrust clinical program.

The filing states that the webcast is scheduled for Monday, November 9, 2026, at 8:00 a.m. Eastern Time. The disclosed purpose of the event is to review initial clinical data evaluating NKX019 in myositis and systemic sclerosis, with the data being presented at the American College of Rheumatology (ACR) Convergence 2026. No additional details regarding the clinical data findings were included in the body of the 8-K itself; the press release containing further information was furnished as Exhibit 99.1.

The company noted in the filing that the information disclosed under Item 7.01, including Exhibit 99.1, is being "furnished" and "shall not be deemed 'filed'" for purposes of Section 18 of the Securities Exchange Act of 1934. The report was signed by Nadir Mahmood in his capacity as President of Nkarta, Inc.

What Was Disclosed

Nkarta, Inc. reported via an 8-K filed November 6, 2026, that it will host a November 9, 2026 webcast reviewing initial Ntrust clinical data for NKX019 in myositis and systemic sclerosis, presented at ACR Convergence 2026.